TITLE

WEEK IN WASHINGTON

PUB. DATE
June 2012
SOURCE
BioWorld Insight;6/11/2012, Vol. 20 Issue 24, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers the news briefs related to the pharmaceutical industry in the U.S. as of June, 2012 on topics including regulatory challenges, survey of pharmacy drug prices by the U.S. Centers for Medicare & Medicaid Services and biosimilars naming.
ACCESSION #
76926989

 

Related Articles

  • Disclosure rule open for comments. Elliott, William T. // Infectious Disease Alert;Mar2012 Pharmacology, p2 

    The article reports on the comments being sought by the U.S. Centers for Medicare and Medicaid Services on a proposed rule that would require drug and device companies to report all financial relationships with physicians.

  • Analysts Predict Slower DTC Growth. Wechster, Jill // Pharmaceutical Executive;Apr2002, Vol. 22 Issue 4, p26 

    Presents a prediction on pharmaceutical expenditures in the U.S. from 2000 to 2011. Details of a report on healthcare spend from the U.S. Office of the Actuary in the Centers for Medicare and Medicaid Services; Expectations of analysts on products that will be lunched in the pharmaceutical...

  • MMIS says awareness still lacking in Sunshine Act. FORD, OMAR // Medical Device Daily;3/ 1/2013, Vol. 17 Issue 41, p1 

    The article presents a report from communication solutions developer MMIS Inc. based in Portsmouth, New Hampshire which reveals that physicians have lack information about the U.S. Sunshine Act. It notes that the regulation was released by the Centers for Medicare & Medicaid Services and is...

  • CMS final Sunshine Act Transparency Rule: Managed care and hospital impacts. Marcoux, Rita; Collins, Charles; Vogenberg, F. Randy // Formulary;Apr2013, Vol. 48 Issue 4, p153 

    The article presents information on new regulations released by the U.S. Centers for Medicare & Medicaid Services (CMS) on February 1, 2013, for the implementation of the Physician Payment Sunshine Act (PPSA). The PPSA was included in the Affordable Care Act (ACA) of 2010 to provide transparency...

  • CMS sets timeline for Sunshine Act implementation. Lee, Jaimy // Modern Healthcare;2/4/2013, Vol. 43 Issue 5, p4 

    The article reports that the Centers for Medicare and Medicaid Services (CMS) in the U.S. has issued a final rule for the Physician Payments Sunshine Act, which aimed to increase transparency and reduce the potential for conflicts of interest in the healthcare industry.

  • WHERE DOES THE SUN SHINE? THE REGULATORY ENVIRONMENT FOR EDUCATION AND PROMOTIONS*. Harting, Donald // AMWA Journal: American Medical Writers Association Journal;Winter2013, Vol. 28 Issue 4, p162 

    Information about a discussion on the regulatory environment for education and promotion held at the 2013 American Medical Writers Association (AMWA's) 73rd Annual Conference in Columbus, Ohio on November 8, 2013 is presented. The session enabled the presentors to tackle on the sunshine law. The...

  • The COMPREHENSIVE PRIMARY CARE INITIATIVE: What You Need to Know. Moore, Kent J. // Family Practice Management;Jan/Feb2012, Vol. 19 Issue 1, p12 

    The author discusses the Comprehensive Primary Care Initiative (CPCI), and explains its importance in family medicine. He mentions that CPCI is a multiplayer initiative led by the Centers for Medicare and Medicaid Services (CMS) to test a service delivery model and a blended payment model that...

  • from our board. ACO uncertainty: How would proposed organizations work -- and would they impact dermatology? Wheeland, Ronald G. // Dermatology Times;Jul2011, Vol. 32 Issue 7, p7 

    The article offers the author's insights on the emergence of accountable care organizations (ACOs) as part of the health care reform proposals as well as its impact on the delivery of dermatologic services. The author contends that small medical practices and private dermatology practices may...

  • Prepare for aftermath after SRDP submission.  // Healthcare Risk Management;Dec2011, Vol. 33 Issue 12, p136 

    The article discusses the financial and regulatory implications of submitting the Stark Voluntary Self-Referral Disclosure Protocol (SRDP) for the healthcare providers.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics